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Abstract: Cardiac amyloidosis is a type of amyloidosis in which one of the affected organs is
the heart.  The disease is characterized by the formation of protein aggregates between the
cells  of  the  organ,  namely  amyloid,  which  disables  its  function.  The  following  types  of
amyloidosis can be distinguished: systemic senile amyloidosis (wild-type ATTR), light chain
amyloidosis (AL) and hereditary transthyretin-related amyloidosis.  The symptoms include,
e.g.,  systolic  dysfunction  or  arrhythmia.  The  treatment  is  focused  on  the  therapy  with
melphalan and, additionally, stem cells transplant and chemotherapy with dexamethasone or
cyclophosphamide. In the advanced stage of the disease, a heart transplant is necessary. The
diagnosis  is  made  on  the  basis  of  laboratory  testing,  electrocardiogram  changes,  and
echocardiography.
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Introduction
The amyloidoses  belong to a group of diseases that cause disorders characterized by
protein flaccidity. In these diseases it is possible to occupy more than one organ by amyloid
deposits. The organ which is occupied by amyloid and the type of amyloid affects  on the
prognosis of the disease. [1] Light-chain (AL) amyloidosis belongs to rare and unfortunately
often  fatal  disease.Its  leading  cause  is  light  chains  misfolding,  which  form soluble  toxic
aggregates that deposit as fibrils (amyloid) in tissue and organs. It results in significant and
permanent organ dysfunction. Practically every organ can be affected by AL amyloidosis but
approximately  70%  of  patients  amyloid  deposits  in  the  cardiac  myocytes.  As  a  result,
ventricular  wall  thickens,  and  that  leads  to  restrictive  cardiomyopathy  and  subsequent
congestive heart failure. [2] 
Cardiac AL - amyloidosis
Amyloid is a fibrillar proteinaceous material which spread out in extracellular space of
the heart in cardiac amyloidosis. The most common type of amyloid protein that occupies the
heart are the immunoglobulin-derived light chain and transthyretin (TTR; previously called
prealbumin). TTR is a type of transporting proteins which is thyroid and retinal (vitamin A)
protein. It is essential to precisely define the precursor protein causing amyloidosis because it
affects the clinical manifestation of the disease and choice of therapies. It is significant to
recognize that cardiac amyloidosis as a part of a systemic illness. [1] Patients with cardiac
amyloidosis have a poor prognosis with eventual  development  of congestive heart  failure,
angina, and arrhythmias. [3] In the past amyloidosis was perceived as a rare condition, often
only diagnosed at autopsy, and was untreatable. Over the last decade, huge progress has been
made, both in diagnosis and treatment of cardiac amyloidosis. The disease first symptoms
appear from the fifth to seventh decade. However, it can occur at any age from the fourth
decade onward. [1]
Cardiac involvement is characteristic of three types of primary amyloidosis: hereditary
transthyretin, acquired monoclonal light-chain and systemic senile amyloidosis. The heart is
rarely affected in secondary amyloidosis, and it is clinically non-significant. [4]
Hereditary transthyretin-related amyloidosis
This familial type of cardiac amyloidosis is associated with autosomal dominant TTR
gene mutation  found on chromosome 18 (18q23).  There are over 100 different  mutations
encoding variant TTR described and they concern a single nucleotide polymorphism. [4,5]
The most common mutation regards substitution of valine with methionine at position 30.
[4,7,8]  The  new  variant  of  a  transport  protein  (TTR)  has  destabilized  tetramers  which
dissociate  forming  monomers.  They tend to  misfold  and form the  aggregates  of  amyloid
fibrils.  Carriers  of  the  mutation  have  no  amyloid  deposition  until  adulthood  for  the
development of the disease is probably associated with aging. The onset of the disease varies




Light-chain amyloidosis  occurs in 8.9 per million people per year and is  the most
common and the most severe form of cardiac amyloidosis. AL occurs approximately evenly
in men and women. [6,9] Small plasma cell clones are involved in this type of amyloidosis.
They produce monoclonal immunoglobulin light chains, which are secreted extracellularly
(either as a fragment or an entire molecule) and form fibril composed of monoclonal kappa or
lambda LCs. These abnormal proteins misfold instead of forming the α-helical structure and,
as a result, produce amyloid. [4,6,10] This process is responsible for systemic toxicity, the
devastation of the organ and cardiac failure. [9] 
Systemic senile amyloidosis (wild-type ATTR)
The prevalence rate of systemic senile amyloidosis (SSA) is at about 10% in patients
aged >80 years. Furthermore, estimations show that half of the population aged >90 years
may suffer from SSA. Systemic senile amyloidosis has a higher morbidity rate in men than in
women. [4] In spite of the ‘systemic disease’ term, the heart is usually the only affected organ.
Wild-type transthyretin  builds up in the heart  tissue while  TTR mutations  are  absent.  [8]
Those  deposits  are  structurally  unstable,  leading  to  expansion  of  misfolded  intermediates
which then aggregate and form amyloid. Wild type ATTR may contribute to heart failure with
preserved ejection fraction. [11]
Symptoms
Cardiac  amyloidosis,  independently  of  type,  appears  as  restrictive  cardiomyopathy
defined  by  continuous  progress  of  diastolic  and  subsequently  systolic  dysfunction  and
arrhythmia of both cardiac ventricles. [12] Diagnosis is frequently delayed as a result of its
numerous nonspecific manifestations. The spectrum of possible presentations may be very
different and range from asymptomatic stage to NYHA IV heart failure. Commonly fatigue,
exertional dyspnea, hepatic congestion or pedal edema are early findings. [12,13] The other
frequent  symptoms  include  –  lightheadedness,  angina  pectoris,  ascites  and  right  upper
quadrant pain attributable to congestive or infiltrative hepatomegaly. [13,14]  Rarely present
chest  pain  can  be  attributed  to  amyloid  infiltration  of  small  inner  vessels  of  the  heart.
[14,15,16] Atrial and ventricular arrhythmias are common findings. The most frequent early
arrhythmia is atrial fibrillation, with ventricular fibrillation emerging in a later stage of the
disease.  [15]  Syncopal  episodes  may  derive  from  autonomic  neuropathy  as  well  as
electromechanical  dissociation and ventricular  arrhythmias.  Exertional  syncope could stem
from the insufficient  cardiac  output  in  these patients  with decreased ability  to  adequately
increase the heart rate. [12,14] Syncope due to autonomic neuropathy, bradycardia or heart
block does not prognosticate well and is equivalent to a high risk of death. Multiple other
noncardiac  symptoms  such  as  dry  mouth,  purpura,  bleeding,  defecation  abnormalities,
paresthesias, and hoarseness may accompany especially in AL type of cardiac amyloidosis.
The pathognomic features of AL amyloidosis – macroglossia and periorbital ecchymosis are
present only in the minority. [12,14] AL amyloidosis cardiomyopathy is restrictive therefore
chest x-ray (CXR) may not show any abnormalities. [17]                      
Classically, a patient with AL cardiac amyloidosis suffers from symptoms caused by rapid
expansion of congestive diastolic heart failure and subsequent right-sided systolic dysfunction
produced by right ventricular wall thickening secondary to amyloid deposition. [13] However,
because of the overlapping manifestations it is imprudent to rely solely on clinical symptoms.
[14]
Diagnosis of amyloidosis
Amyloidosis is a disease that is relatively difficult  to diagnose. The most common
method is a heart muscle biopsy which enables identification of proteins forming amyloid.
The  biopsy  specimen  is  evaluated  immunohistochemically  and  histologically  by  use  of
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thioflavin and Congo red. In case of a negative result, another tissue needs to be sectioned to
confirm  amyloidosis.  [18,19,21]  Immunohistochemical  tests  have  lower  sensitivity  than
histological ones due to the structure of amyloid. 
In some cases  for diagnostic  confirmation  of  amyloidosis  amyloid  sequencing and
serum amyloid P scintigraphy are required, but those methods have little diagnostic value as a
large amount  of blood is  present in  both atria  and ventricles  which may result  in  a false
outcome. [19,21]
Electrophoresis is another diagnostic method which helps to observe the monoclonal
protein. Due to its low sensitivity, it is not used as a diagnosis confirmation. [19,21]
Laboratory testing  is  significant  in  the process  of diagnosis.  It  reveals  proteinuria,
increased  level  of  creatinine  and  alkaline  phosphatase.  The  necrosis  of  cardiomyocytes
probably causes a high concentration of troponins. The necrosis is a consequence of heart
cells ischemia because of amyloid deposition or vessel occlusion with amyloid fiber. BNP
concentration is also high as ventricles are filled with blood during blood pressure increase.
BNP and troponin I bespeak a poor prognosis of amyloidosis course. [20]
CXR  shows  a  physiological  cardiac  silhouette,  or  it  is  slightly  enlarged.  On
electrocardiogram the QRS complex is low-amplitude as a result of healthy cardiomyocytes
mass  decrease,  changes  ensuing heart  attack,  atrial  fibrillation,  heart  axis  deviation,  first-
degree atrioventricular block and ventricular tachycardia. [20]
Echocardiography  exhibits  granular,  spotty  heart  walls  which  are  considerably
enlarged just as the size of atria, thickness of interatrial and interventricular septa. The size of
ventricles is unchanged. The symptoms of diastolic, restrictive heart failure are present. When
the disease is advanced, there are also signs of systolic heart failure. [20] Cardiac amyloidosis
diagnosis criteria according to Gertz et al. from 2005 include heart wall enlargement >12mm
found in echocardiography and lack of other possible causes of hypertrophy. [21]
In the course of cardiac amyloidosis ‘square root sign’ is present. It is characterized by
a significant fall in pressure in the first phase of diastole with a subsequent sudden rise. This
sign is also present in constrictive pericarditis, but the slower filling of left ventricle in the
first phase in amyloidosis allow to differentiate these diseases. [20]
Treatment
The progress and intensification of cardiac AL amyloidosis treatment depend on the
clinical state of a patient. The therapy strategy is modified individually; therefore, the earlier
diagnosis is made and the treatment implemented, the greater the therapeutic success.
Currently, the treatment of choice is melphalan in high doses (HDM) combined with
autologous stem cells transplant (ASCT). Patients with >10% of plasma cells in their bone
marrow are advised to undergo induction chemotherapy (bortezomib + cyclophosphamide +
dexamethasone) with following ASCT. This method has relatively high efficiency and allows
to avoid burdensome continuous chemotherapy.
Unfortunately ASCT is not possible in all patients. High-risk patients, who would not
survive such a strong cytotoxic therapy due to, e.g., end-stage heart failure, are recommended
oral  treatment  with  melphalan  and  dexamethasone  (MDex).  So  far,  ASCT has  not  been
proven to have a greater efficiency than MDex. Certain conditions need to be fulfilled to meet
the transplant qualification terms, so most of the patients (about 80-85%) undergo the second
option of treatment. [22,27]
Another important alternative to transplant is proteasome inhibitors. The proteasome is
an  enzymatic  complex  that  takes  part  in  most  of  the  processes  of  proteins  degradation
(including amyloid) in eukaryotic cells, leading to intracellular homeostasis maintenance. [23]
It was confirmed that using proteasome inhibitors in monotherapy cause light chain amyloid
decline  and  clinical  improvement  among  those  patients.  The  combination  of
337
cyclophosphamide with dexamethasone (CVD) is at the moment the first-line treatment for
patients with cardiac AL amyloidosis who are not qualified directly to ASCT. This method is
also  used  as  induction  or  consolidation  just  after  or  before  HDM with  ASCT.  Study on
ixazomib, an oral proteasome inhibitor, is ongoing and phase I and II results are promising.
However, the final results are not available yet and are going to be released in August 2022.
[24,27,28]
Recurrent and resistant AL amyloidosis is treated with good results with thalidomide,
lenalidomide, and pomalidomide. However, thalidomide and lenalidomide are not frequently
used,  because  of  their  low-profile  safety.  Research  on pomalidomide,  on  the  other  hand,
provided us with auspicious data. Study on the positive impact of doxycycline is being carried
out because it was proven that patients taking this drug as infection prophylaxis after stem
cells  transplant  achieve  better  hematologic  response  and  higher  survival  rates  than  with
penicillin therapy. [28]
One of the wild-type ATTR and ATTRm treatment methods are liver or liver and heart
transplant. Due to limited organs availability and chronic immunosuppression after surgery,
the therapy has little value, and there is a need for an alternative treatment. One of them is
transthyretin synthesis inhibition. Patisiran, a small interfering RNA (siRNA), binds specific
sequences  on  messenger  RNA,  silence  them  and  inhibits  protein  synthesis.  Antisense
nucleotides and their ability to specifically bind to RNA and inhibit transthyretin translation
are being analyzed. However, these results are not as positive as the previous ones. [25]
Another  drug, Tafamidis,  which binds to  transthyretin  and inhibit  amyloidogenesis
looks promising. Phase III of the study, showed a significant decrease in the number of both,
hospitalizations  due  to  cardiovascular  reasons,  and  mortality  in  a  group  of  patients  with
transthyretin amyloid cardiomyopathy taking Tafamidis versus placebo. [26,28,29]
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